Results 81 to 90 of about 7,984 (250)

MJA Practice Essentials - 2: Recent advances in therapy of diabetes - Endocrinology [PDF]

, 2003
The document attached has been archived with permission from the editor of the Medical Journal of Australia. An external link to the publisher’s copy is included.As suboptimal blood glucose control has a lasting harmful effect even if control improves ...
Chan JL, Jones TW, Moore‐Sullivan TM, The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus, Wang F, Weissberg‐Benchell J, White NH   +6 more
core   +1 more source

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Abhay Kumar Sahoo, Sambit Das, Pitambar Prusty, Anand Shankar, Shaibal Guha   +4 more
doaj   +1 more source

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring

Diabetes, Metabolic Syndrome and Obesity, 2011
Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical ...
Abe S, Inoue G, Yamada S, Irie J, Nojima H, Tsuyusaki K, Usui K, Atsuda K, Yamanouchi T   +8 more
doaj  

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Hyderabad cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
R Santosh, Ravi Mehrotra, N G Sastry
doaj   +1 more source

Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study. [PDF]

Hormones (Athens), 2023
Kazakou P, Paschou SA, Mitropoulou M, Vasileiou V, Sarantopoulou V, Anastasiou E.   +5 more
europepmc   +1 more source

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog

Vascular Health and Risk Management, 2010
Katarina RaslovaMetabolic Center Ltd and Slovak Medical University, Bratislava, Slovak RepublicAbstract: Basal insulin analogs are used to minimize unpredictable processes of NPH insulin.
Katarina Raslova
doaj  

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A 1 chieve study

Indian Journal of Endocrinology and Metabolism, 2013
Background: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Jothydev Kesavadev
doaj   +1 more source

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study [PDF]

, 2013
Aims/hypothesis: Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new basal insulin with an ultra-long flat action profile.
AE Gold, AJ Garber, B Raju, B Zinman, BM Frier, CG Fanelli, CR Bowie, D Wechsler, F Smeeton, I Jonassen, IJ Deary, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, KI Birkeland, O Tschritter, P Galassetti, P Rossetti, PA Goldberg, RE Ratner, RE Ratner, RJ McCrimmon, RM Reitan, RT Wilkinson, S Dagogo-Jack, S Heller, S Heller, SCL Gough, SN Davis, T Heise, UK Hypoglycaemia Study Group, V McAulay, World Medical Association   +30 more
core   +2 more sources

Insulin detemir for the treatment of obese patients with type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2012
Priscilla A Hollander1,21Baylor Endocrine Center, 2Baylor Medical Center, Dallas, Texas, USAAbstract: The risk for developing type 2 diabetes (T2DM) is greater among obese individuals. Following onset of the disease, patients with T2DM become more likely
Hollander PA
doaj  

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK. [PDF]

Diabetes Ther, 2021
Husemoen LLN, Mørch LS, Christensen PK, Hartvig NV, Feher MD.   +4 more
europepmc   +1 more source